Seasoned financial executive with experience across financial reporting, capital markets, strategic planning and operations.- Spent past 4 years at Mirimus, helping to scale a unique approach to PCR testing during the pandemic. We grew revenues more than 10x to support post-pandemic R&D projects, culminating in the spinout of Micoy Therapeutics which is targeting specific autoimmune conditions that are highly correlated with severe reactions to Covid and other viral infections.- Previously, a senior equity research analyst at UBS, where I covered US banks among other companies and built strong relationships with senior executives and institutional investors, including regarding IPOs and other capital markets transactions. I also honed my modelling and financial analysis expertise, and developed writing skills I take pride in.- Began my career at PwC, where I got a strong foundation in accounting and financial statements, and then transitioned to the M&A group, where I was exposed to significant acquisition and restructuring transactions.